Previous 10 | Next 10 |
Shares of Lipocine Inc. (NASDAQ:LPCN) traded at a new 52-week low today of $0.34. So far today approximately 414,000 shares have been exchanged, as compared to an average 30-day volume of 993,000 shares. Lipocine Inc. has overhead space with shares priced $0.35, or 80.3% below the average con...
New York, New York--(Newsfile Corp. - December 12, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lipocine Inc. (NASDAQ: LPCN) ("Lipocine" or the "Company") of the January 14, 2020 deadline to seek the role of lead plaintiff in a federal securiti...
NEW YORK , Dec. 11, 2019 /PRNewswire/ -- Carolina Financial Corporation (CARO) Lifshitz & Miller announces investigation into possible breach of fiduciary duties in connection with the sale of CARO to United Bankshares, Inc. for 1.13 United shares per CARO share. If you are ...
Lipocine (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, closed its underwritten public offering of 10,450,000 Class A Units priced at $0.50 each and 1,550,000 Class B Units for $0.4999 each, resulting in gross proceeds of approximately ...
SALT LAKE CITY , Nov. 18, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the closing of a public offering of (i) 10,450,000 Class A Units, each consisting of shares of its co...
New York, New York--(Newsfile Corp. - November 15, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Lipocine Inc. (NASDAQ: LPCN) ("Lipocine" or the "Company") of the January 14, 2020 deadline to seek the role of lead plaintiff in a federal securiti...
Lipocine ( LPCN -34.6% ) prices its public offering of 10.45M Class A Units at $0.50 and 1.55M Class B Units at $0.4999. More news on: Lipocine Inc., Healthcare stocks news, Stocks on the move, Read more ...
SALT LAKE CITY , Nov. 14, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the pricing of a public offering of (i) 10,450,000 Class A Units, each consisting of shares...
SALT LAKE CITY , Nov. 13, 2019 /PRNewswire/ -- Lipocine Inc. (NASDAQ:LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units consisting of shares of its common stock (or pre-funded warrants)...
Lipocine (NASDAQ: LPCN ): Q3 GAAP EPS of -$0.12 beats by $0.11 . More news on: Lipocine Inc., Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-27 02:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study PR Newswire Met standard bioequivalence (BE) criteria C max, AUC 0-t , and AUC 0- ∞ C trough criterion was met LPCN 1154 was well tolerat...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...